Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityCASI / CASI Pharmaceuticals, Inc. (14757U109)
CEO and DirectorRen Ken
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Institutional Owners50
Institutional Shares5,266,541 - 6.11%
Common Shares Outstanding86,145,298 shares (as of 2018-03-31)
Institutional Value$ 21,134,000 USD

Institutional Stock Ownership and Shareholders()

CASI / CASI Pharmaceuticals, Inc. Institutional Ownership

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has 50 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,266,541 shares. Largest shareholders include Vanguard Group Inc, Wellington Shields Capital Management, LLC, Wellington Shields & Co., LLC, Millennium Management Llc, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Geode Capital Management, Llc, Goldman Sachs Group Inc, Susquehanna International Group, Llp, and California Public Employees Retirement System.
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/casi"><img src="https://images.fintel.io/us-casi-so.png" alt="CASI / CASI Pharmaceuticals, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR Virtu Financial LLC 12,124 0 -100.00 39 0 -100.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 1,721 21 -98.78 5 0 -100.00
2018-05-09 13F-HR IFP Advisors, Inc 2 2 0.00 0 0
2018-05-14 13F-HR MORGAN STANLEY 43,767 95,512 118.23 141 398 182.27
2018-05-15 13F-HR Advisor Group, Inc. 90 90 0.00 0 0
2018-05-18 13F-HR Moors & Cabot, Inc. 24,663 22,935 -7.01 82 96 17.07
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 24,541 140,680 473.24 80 587 633.75
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 225,650 225,650 0.00 250 259 3.60
2018-05-15 13F-HR VANGUARD GROUP INC 936,186 1,285,475 37.31 3,042 5,360 76.20
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 10,883 10,949 0.61 35 46 31.43
2018-04-20 13F-HR Steward Partners Investment Advisory, Llc 45 45 0.00 0 0
2018-05-14 13F-HR Renaissance Technologies LLC 150,600 41,800 -72.24 489 174 -64.42
2018-05-09 13F-HR Private Advisor Group, LLC 15,000 63
2018-05-07 13F-HR Penobscot Investment Management Company, Inc. 0 27,000 0 113
2018-05-15 13F-HR Bank of New York Mellon Corp 36,880 154
2018-05-15 13F-HR STATE STREET CORP 23,629 99
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 1,000 6,695 569.50 3 28 833.33
2018-05-09 13F-HR BlackRock Inc. 386,090 382,001 -1.06 1,254 1,593 27.03
2018-05-15 13F-HR PERCEPTIVE ADVISORS LLC 83,682 43,682 -47.80 272 182 -33.09
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 50 60 20.00 0 0
2018-05-03 13F-HR Wellington Shields Capital Management, LLC 725,348 790,256 8.95 2,357 3,295 39.80
2018-05-07 13F-HR Focused Wealth Management, Inc 45 45 0.00 0 0
2018-05-15 13F-HR UBS Group AG 10,872 5,373 -50.58 35 23 -34.29
2018-04-27 13F-HR Chicago Partners Investment Group LLC 27 27 0.00 0 0
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 0 354 0 3
2018-05-16 13F-HR Alpine Partners VI, LLC 27,729 11,954 -56.89 90 50 -44.44
2018-05-14 13F-HR PRICE T ROWE ASSOCIATES INC /MD/ 50,400 49,400 -1.98 164 206 25.61
2018-05-15 13F-HR Verition Fund Management LLC 15,835 66
2018-05-03 13F-HR Wellington Shields & Co., LLC 445,118 625,118 40.44 1,447 2,607 80.17
2018-05-14 13F-HR IHT Wealth Management, LLC 7,000 7,000 0.00 25 30 20.00
2017-02-10 13F-HR BlackRock Fund Advisors 35,958 37,886 5.36 40 44 10.00
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 2,871 2,726 -5.05 9 11 22.22
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 42,214 430,297 919.32 137 1,794 1,209.49
2018-04-16 13F-HR Raymond James Financial Services Advisors, Inc. 20,090 52,090 159.28 65 217 233.85
2018-05-14 13F-HR Laurion Capital Management LP 55,729 232
2018-05-10 13F-HR JP Morgan Chase & Co 9 9 0.00 0 0
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 45 2,046 4,446.67 0 8
2017-02-10 13F-HR BlackRock Investment Management, LLC 3,375 3,375 0.00 4 4 0.00
2018-05-11 13F-HR CITADEL ADVISORS LLC 20,097 84
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 136,518 136,518 0.00 444 569 28.15
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 225,578 225,578 0.00 733 940 28.24
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 17,649 17,545 -0.59 58 74 27.59
2018-05-15 13F-HR ELEMENT CAPITAL MANAGEMENT LLC 29,279 122
2017-02-10 13F-HR BlackRock Advisors LLC 7,740 7,740 0.00 9 9 0.00
2018-05-17 13F-HR Atlantic Trust Group, LLC 100 100 0.00 0 0
2018-05-15 13F-HR Jefferies Group LLC 27,000 113
2018-04-20 13F-HR EVERETT HARRIS & CO /CA/ 10,002 10,002 0.00 33 42 27.27
2018-05-09 13F-HR NORTHERN TRUST CORP 73,987 73,987 0.00 240 308 28.33
2018-05-15 13F-HR BARCLAYS PLC 66,720 46,200 -30.76 217 193 -11.06
2018-05-15 13F-HR BlueCrest Capital Management Ltd 26,709 111
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 18,861 178,063 844.08 61 743 1,118.03
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 18,398 20,097 9.23 60 84 40.00

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Week In Review: CITIC Offers $3.6 Billion To Acquire China Biologic

2018-06-24 seekingalpha
CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products (NASDAQ:CBPO), one of China's top five plasma-based biopharmas. The bid, which came at a 34% premium to the previous close, was unsolicited and non-binding. Headquartered in Beijing, CBPO operates plasma-gathering facilities and offers 20 plasma-based products. The offer, priced at $110 per share, represents a P/E ratio of 37 based on the past 12 months, but only 16. (76-1)

Spectrum Pharmaceuticals' (SPPI) CEO Joe Turgeon on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Good day, ladies and gentlemen, and welcome to Spectrum Pharmaceuticals First Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, today’s conference is being recorded. (10-2)

Week In Review: James Watson To Lead New Shenzhen Biopharma Research Center

2018-03-25 seekingalpha
James Watson, who co-discovered the double-helix structure of DNA in 1953, will lead a new international life science research center in the International Bio Valley, located in Shenzhen's Dapeng New Area. A groundbreaking ceremony was held last Friday with Dr. Watson in attendance. The new research center, which may be called the Watson Research Center of Life Science, will strive to find new, less expensive solutions to the problem of cancer and will be staffed by more than 1,000 scientists. (18-0)

Your Daily Pharma Scoop: Arena Soars, Roche Data, GlaxoSmithKline Commences Study

2018-03-21 seekingalpha
GlaxoSmithKline commences late stage study with Benlysta (belimumab) and Roche's Rituxan (rituximab) in adult patients with systemic lupus erythematosus (SLE). (26-1)

CUSIP: 14757U109